Business · 21/04/1999
FDA Releases Draft Guidance for INDs in Phase 2 and 3 Drug Studies
The FDA has made available a draft guidance document outlining recommendations for sponsors of INDs on chemistry, manufacturing, and controls documentation for phase 2 and 3 studies of human drugs and biotechnology-derived products.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →